A transatlantic team of researchers led by the University of Leicester is using an innovative genetic approach to treating neurodegenerative disorders such as Huntington's disease.
By studying baker's yeast, the team were able to fathom various aspects of the disease and understand the genes and cellular pathways it uses.
The research suggests that pharmacological modulation of translation may be a fruitful avenue for treatment in future.
"Our research has taken advantage of cutting edge genomics approaches using a simple model organism to identify a novel area for potential therapeutic intervention for Huntington's disease," said Flaviano Giorgini, lead author of the study.
The universities of Lisbon and California at San Francisco were also involved in the study, which was funded by the Medical Research Council.
Recently, International Stem Cell Corporation welcomed an announcement by scientists at the Nationwide Children's Hospital showing the use of parthenogenetic stem cells to treat Huntington's disease.
Find out how Barchester works to create safe and understanding environments for those living with Huntington's Disease.